Cancer Drug
-
{
- All
- News
- Videos
-
India's Cancer Affordability: Cheaper Drugs Alone Cannot Save More Lives
Price control is not the answer to India's cancer problem. What it needs is a comprehensive strategy of transparent pharmaceutical pricing, indigenous innovation, rational treatment protocols, evidence-based reimbursement and equitable health care delivery.
-
Explained: Why Are Some Drugs Cheaper, Others Expensive For Cancer?
Price reductions have been seen in drugs that are used to treat different cancers. However, the price cuts have not been uniform. Several expensive medicines have remained unchanged. This raises an important question: why do some cancer drugs cost much less while others continue to be expensive.
-
Cancer Drug Prices Slashed By Over 90%, But Experts Say One-Time Cuts Won't End Overpricing
Public health group, Jan Swastha Abhiyaan has demanded cost-based price controls, permanent caps on trade margins and independent verification of cancer drug prices.
-
Cancer Drugs Price Cut: Generics Get Cheaper, But The Most Expensive Medicines Escape The Cut
The National Pharmaceutical Pricing Authority (NPPA) has revised the maximum retail prices (MRPs) of 543 cancer drug brands and pack sizes after the government capped trade margins on 137 non-scheduled anti-cancer medicines at 30 per cent.
-
Cancer Drug Price Cut: Govt Caps Trade Margins At 30%, Revises Prices Of 543 Drug Brands
Cancer patients could see lower medicine bills as the NPPA revises maximum retail prices for 543 anti-cancer drug brands. The new rates take effect on November 9, 2026, with some listed medicines recording substantial price reductions.
-
Cancer Drug Prices Slashed: New Rates For 543 Drug Brands From November 9
The new MRPs will apply from November 9, 2026. The NPPA's latest list is based on the price information submitted by companies until October 27.
-
Supreme Court Flags Massive Gap Between Medicine MRP And Retailer Cost, Asks Government, "Allowing This To Happen?"
The Court was hearing a public interest litigation (PIL) filed by advocate Kishan Chand Jain seeking mandatory generic drug prescriptions, strict initial price controls on non-scheduled medicines, and statutory margin caps on medical devices under the Drug Price Control Order (DPCO).
-
AstraZeneca's Experimental Stomach Cancer Drug Doubles Survival In Trial
AstraZeneca's experimental antibody-drug conjugate sonesitatug vedotin has doubled overall survival in a late-stage trial for advanced stomach cancer patients, offering renewed hope for hard-to-treat gastric cancers across global populations.
-
137 Cancer Drugs To See Up To 70% Price Cut From November 9
The revised, lower prices are scheduled to officially take effect on November 9, 2026. Patients can check revised prices on the NPPA website and Pharma Sahi Daam app.
-
Government Caps Cancer Drug Trade Margins At 30%, Supreme Court Asks: Why Regulate Only Cancer Medicines?
While the proposed cap could reduce cancer treatment costs, the Supreme Court wants the government to explain why similar restrictions cannot be considered for other medicines and medical devices.
-
After Cancer Drug Price Cap, Karnataka Seeks Similar Relief For Heart, Kidney Patients
Karnataka has asked the Centre to extend price safeguards to expensive medicines used for cardiac and kidney diseases after the government approved a 30% trade-margin cap for non-scheduled anti-cancer drugs.
-
Karnataka Flags Wide Disparity Between Landing Cost And MRP Of High-Cost Drugs And Medical Consumables, Seeks Central Government Intervention
Recent investigations by the Karnataka Food Safety and Drug Administration (FDA) have revealed that pharmaceutical companies are supplying medicines to hospitals at heavily discounted institutional (landing) prices, while patients are being billed at or near the printed MRP.
-
Supreme Court Questions Centre Over Massive Markup Gaps In Cancer Drug Prices
The Supreme Court questioned the Centre over huge differences between the MRP and PTR of cancer drugs, asking why essential life-saving items lack price control.
-
'Smart' Cancer Drug To Target Tumour Cells, Spare Healthy Ones: May Change Cancer Treatment
A new smart cancer drug targets tumour cells while sparing healthy ones, offering hope for safer and more effective cancer treatment.
-
New Landmark Drug Nearly Doubles Survival In Advanced Pancreatic Cancer, FDA Approves
The US FDA has approved daraxonrasib, a targeted oral drug for previously treated metastatic pancreatic cancer. In a 500-patient trial, it nearly doubled median overall survival compared with standard chemotherapy
-
India's Cancer Affordability: Cheaper Drugs Alone Cannot Save More Lives
Price control is not the answer to India's cancer problem. What it needs is a comprehensive strategy of transparent pharmaceutical pricing, indigenous innovation, rational treatment protocols, evidence-based reimbursement and equitable health care delivery.
-
Explained: Why Are Some Drugs Cheaper, Others Expensive For Cancer?
Price reductions have been seen in drugs that are used to treat different cancers. However, the price cuts have not been uniform. Several expensive medicines have remained unchanged. This raises an important question: why do some cancer drugs cost much less while others continue to be expensive.
-
Cancer Drug Prices Slashed By Over 90%, But Experts Say One-Time Cuts Won't End Overpricing
Public health group, Jan Swastha Abhiyaan has demanded cost-based price controls, permanent caps on trade margins and independent verification of cancer drug prices.
-
Cancer Drugs Price Cut: Generics Get Cheaper, But The Most Expensive Medicines Escape The Cut
The National Pharmaceutical Pricing Authority (NPPA) has revised the maximum retail prices (MRPs) of 543 cancer drug brands and pack sizes after the government capped trade margins on 137 non-scheduled anti-cancer medicines at 30 per cent.
-
Cancer Drug Price Cut: Govt Caps Trade Margins At 30%, Revises Prices Of 543 Drug Brands
Cancer patients could see lower medicine bills as the NPPA revises maximum retail prices for 543 anti-cancer drug brands. The new rates take effect on November 9, 2026, with some listed medicines recording substantial price reductions.
-
Cancer Drug Prices Slashed: New Rates For 543 Drug Brands From November 9
The new MRPs will apply from November 9, 2026. The NPPA's latest list is based on the price information submitted by companies until October 27.
-
Supreme Court Flags Massive Gap Between Medicine MRP And Retailer Cost, Asks Government, "Allowing This To Happen?"
The Court was hearing a public interest litigation (PIL) filed by advocate Kishan Chand Jain seeking mandatory generic drug prescriptions, strict initial price controls on non-scheduled medicines, and statutory margin caps on medical devices under the Drug Price Control Order (DPCO).
-
AstraZeneca's Experimental Stomach Cancer Drug Doubles Survival In Trial
AstraZeneca's experimental antibody-drug conjugate sonesitatug vedotin has doubled overall survival in a late-stage trial for advanced stomach cancer patients, offering renewed hope for hard-to-treat gastric cancers across global populations.
-
137 Cancer Drugs To See Up To 70% Price Cut From November 9
The revised, lower prices are scheduled to officially take effect on November 9, 2026. Patients can check revised prices on the NPPA website and Pharma Sahi Daam app.
-
Government Caps Cancer Drug Trade Margins At 30%, Supreme Court Asks: Why Regulate Only Cancer Medicines?
While the proposed cap could reduce cancer treatment costs, the Supreme Court wants the government to explain why similar restrictions cannot be considered for other medicines and medical devices.
-
After Cancer Drug Price Cap, Karnataka Seeks Similar Relief For Heart, Kidney Patients
Karnataka has asked the Centre to extend price safeguards to expensive medicines used for cardiac and kidney diseases after the government approved a 30% trade-margin cap for non-scheduled anti-cancer drugs.
-
Karnataka Flags Wide Disparity Between Landing Cost And MRP Of High-Cost Drugs And Medical Consumables, Seeks Central Government Intervention
Recent investigations by the Karnataka Food Safety and Drug Administration (FDA) have revealed that pharmaceutical companies are supplying medicines to hospitals at heavily discounted institutional (landing) prices, while patients are being billed at or near the printed MRP.
-
Supreme Court Questions Centre Over Massive Markup Gaps In Cancer Drug Prices
The Supreme Court questioned the Centre over huge differences between the MRP and PTR of cancer drugs, asking why essential life-saving items lack price control.
-
'Smart' Cancer Drug To Target Tumour Cells, Spare Healthy Ones: May Change Cancer Treatment
A new smart cancer drug targets tumour cells while sparing healthy ones, offering hope for safer and more effective cancer treatment.
-
New Landmark Drug Nearly Doubles Survival In Advanced Pancreatic Cancer, FDA Approves
The US FDA has approved daraxonrasib, a targeted oral drug for previously treated metastatic pancreatic cancer. In a 500-patient trial, it nearly doubled median overall survival compared with standard chemotherapy
